Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed invasive breast cancer * HER2-negative disease * IHC 0/1 OR IHC 2+ and FISH negative * Must meet 1 of the following criteria: * Unifocal tumor meeting 1 of the following criteria: * T2 or T3 tumors (radiological size \> 20 mm) * T4 tumor of any size with direct extension to the chest wall or the skin * Inflammatory carcinoma with tumor of any size * Multifocal tumor meeting the following criteria: * The sum of each tumors' maximum diameter must be ≥ 20 mm (total radiological tumor size ≥ 20 mm) * Other locally advanced disease meeting 1 of the following criteria: * Any T stage with involvement of large or fixed axillary lymph nodes (radiological diameter \> 20 mm or clinical N2) and primary breast tumor of any diameter * Any T stage with involvement of large or fixed axillary lymph nodes (radiological diameter \> 20 mm or clinical N2), without a primary breast tumor identified and the presence of breast cancer in a lymph node must be histopathologically confirmed by lymph node biopsy (tru-cut or whole lymph node) * Embedded paraffin tumor block available from pre-chemotherapy biopsy and surgical specimen * Bilateral disease allowed * No evidence of metastatic disease * No prior breast cancer except for ductal carcinoma in situ of the breast surgically cured \> 10 years ago * Any hormone receptor status PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * WBC \> 3 x 10\^9/L * Hemogl…